Bolt Biotherapeutics, Inc. (BOLT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

0.7403

+0.0013

(+0.18%)

At close: 04:00PM EDT

Loading interactive chart…

GuruFocus.com
Bolt Biotherapeutics Inc (BOLT) (Q1 2024) Earnings Call Transcript Highlights: Strategic Shifts ...
Key updates include leadership changes, significant workforce reduction, and promising developments in cancer treatment trials.
GlobeNewswire
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team
Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approximately 50%Willie Quinn, Chief Financial Officer, is being appointed as Chief Executive Officer; Randall Schatzman moving to an advisory roleDawn Colburn, Pharm.D., is being promoted to Senior Vice President of Clinical Dev
Simply Wall St.
Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...